SCHEMBL770220

SCHEMBL770220

O=C1CCN(C(=O)CCNC(=O)N2CCCC3CCCCC32)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD11B1 P28845 4/20 0.42
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
DPP4 P27487 4/20 0.35
DPP8 Q6V1X1 2/20 0.35
PKM P14618 1/20 0.34
KMT2A Q03164 1/20 0.34
EPHX2 P34913 2/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770864 0.90 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770244 0.90 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL771182 0.90 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL769965 0.86 NPC1 (0.50) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770958 0.86 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770921 0.84 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770802 0.83 DRD2 (0.41) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770491 0.82 NPC1 (0.44) NPC1RAB9ASMN1; SMN2HSD11B1TDP1
SCHEMBL770598 0.82 NPC1 (0.44) NPC1RAB9ASMN1; SMN2HSD11B1TDP1
SCHEMBL772486 0.82 NPC1 (0.44) NPC1RAB9ASMN1; SMN2HSD11B1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.